AcelRx Pharmaceuticals Inc (ACRX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:AcelRx Pharmaceuticals Inc (ACRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9866
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
AcelRx Pharmaceuticals Inc (AcelRx), is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain. The company’s lead product candidate, Dsuvia (known as Dzuveo outside the US), is a single sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. Its pipeline also includes Zalviso, a drug and device combination product for management of moderate to severe acute pain in adults. AcelRx developed a proprietary, non-invasive, sublingual formulation technology to deliver its highly lipophilic drugs. The company commercializes its EC approved Zalviso under license agreement with Grunenthal in various European Union countries and Australia. AcelRx is headquartered in Redwood City, California, the US.

AcelRx Pharmaceuticals Inc (ACRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AcelRx Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
Leerink Revelation and Industry Ventures Acquire Stake in AcelRx Pharma 11
Partnerships 12
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 12
Equity Offering 14
AcelRx Pharma Raises USD23 Million in Public Offering of Shares 14
Acelrx Pharma Plans to Raise USD40 Million in Public Offering of Shares 16
AcelRx Pharma Completes Public Offering Of Shares For US$51 Million 17
AcelRx Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$6 Million 19
AcelRx Pharma Completes Private Placement Of Units For US$10 Million 21
Asset Transactions 22
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 22
AcelRx Pharmaceuticals Inc – Key Competitors 24
AcelRx Pharmaceuticals Inc – Key Employees 25
AcelRx Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Nov 02, 2018: Acelrx Pharmaceuticals reports third quarter 2018 financial results and provides corporate update 27
Aug 02, 2018: AcelRx Pharmaceuticals reports second quarter 2018 financial results 28
May 09, 2018: AcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results 29
Mar 08, 2018: AcelRx Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 30
Nov 09, 2017: AcelRx Pharmaceuticals Reports Third Quarter 2017 Financial Results 31
Aug 01, 2017: AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 32
May 08, 2017: AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 34
Mar 02, 2017: AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results 36
Corporate Communications 38
Oct 12, 2018: AcelRx Pharmaceuticals Stock Trading Halted 38
Jul 19, 2017: AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer 39
Feb 16, 2017: AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AcelRx Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
AcelRx Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Leerink Revelation and Industry Ventures Acquire Stake in AcelRx Pharma 11
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 12
AcelRx Pharma Raises USD23 Million in Public Offering of Shares 14
Acelrx Pharma Plans to Raise USD40 Million in Public Offering of Shares 16
AcelRx Pharma Completes Public Offering Of Shares For US$51 Million 17
AcelRx Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$6 Million 19
AcelRx Pharma Completes Private Placement Of Units For US$10 Million 21
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 22
AcelRx Pharmaceuticals Inc, Key Competitors 24
AcelRx Pharmaceuticals Inc, Key Employees 25
AcelRx Pharmaceuticals Inc, Subsidiaries 26

List of Figures
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AcelRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AcelRx Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[AcelRx Pharmaceuticals Inc (ACRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Smith & Nephew Plc (SN.)-製薬・医療分野:企業M&A・提携分析
    Summary Smith & Nephew Plc (Smith & Nephew) develops, manufactures and markets medical devices for use in orthopedic reconstruction, orthopedic trauma and clinical therapies, sports medicines and advanced wound management. The company offers its products in various categories including Sports Medici …
  • Italgas SpA-石油・ガス分野:企業M&A・提携分析
    Summary Italgas SpA (Italgas), a subsidiary of Snam SpA, is an oilfield service company that offers transportation and dispatching of natural gas, liquefied natural gas regasification, and storage and distribution of natural gas. The company's activities include rhino-analytical tests; instrumental …
  • NuScale Power LLC-エネルギー分野:企業M&A・提携分析
    Summary NuScale Power, LLC (NuScale), a subsidiary of Fluor Enterprises, Inc., is an energy equipment provider that designs and develops small, light water, and modular nuclear reactors based on light water reactor technology. It offers carbon-free nuclear power through its NuScale Power Module (NPM …
  • Vanda Pharmaceuticals Inc (VNDA):製薬・医療:M&Aディール及び事業提携情報
    Summary Vanda Pharmaceuticals Inc (Vanda Pharmaceuticals) is a specialty pharmaceutical company that develops and commercializesnovel therapies for the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour …
  • Imbalie Beauty Limited:企業の戦略・SWOT・財務情報
    Imbalie Beauty Limited - Strategy, SWOT and Corporate Finance Report Summary Imbalie Beauty Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Fibra Uno Administracion, S. A. De C. V.:企業の戦略・SWOT・財務分析
    Fibra Uno Administracion, S. A. De C. V. - Strategy, SWOT and Corporate Finance Report Summary Fibra Uno Administracion, S. A. De C. V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • SHI International Corp.:企業の戦略的SWOT分析
    SHI International Corp. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Toppan Printing Co Ltd:企業の戦略・SWOT・財務情報
    Toppan Printing Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Toppan Printing Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • EXOR SpA:戦略・SWOT・企業財務分析
    EXOR SpA - Strategy, SWOT and Corporate Finance Report Summary EXOR SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Saline Water Conversion Corp:発電所・企業SWOT分析
    Saline Water Conversion Corp - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Braeburn Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Braeburn Pharmaceuticals Inc (Braeburn), a subsidiary of Apple Tree Partners is a pharmaceutical company that develops novel and long-acting implantable and injectable treatments.The company’s product pipeline includes Probuphine, CAM2038, BB-0417, BB-0817, BB-1216. Its Probuphine, is a a si …
  • Active Biotech AB (ACTI)-製薬・医療分野:企業M&A・提携分析
    Summary Active Biotech AB (Active Biotech) is a biotechnology company that undertakes the development and commercialization of pharmaceuticals in the field of inflammatory/neurodegenerative diseases and cancer. The company has five projects in clinical development of which three have been licensed o …
  • S&T Dynamics Co., Ltd.:企業の戦略・SWOT・財務情報
    S&T Dynamics Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary S&T Dynamics Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Innovation Pharmaceuticals Inc (IPIX):医療機器:M&Aディール及び事業提携情報
    Summary Innovation Pharmaceuticals Inc (Innovation Pharmaceuticals), formerly Cellceutix Corp, is a biopharmaceutical company that discovers and advances medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company provides pipeline products such as kevetr …
  • Mitsui O.S.K. Lines Ltd (9104):企業の財務・戦略的SWOT分析
    Mitsui O.S.K. Lines Ltd (9104) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Alinma Bank:企業の戦略・SWOT・財務分析
    Alinma Bank - Strategy, SWOT and Corporate Finance Report Summary Alinma Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Europa Oil & Gas (Holdings) plc (EOG):企業の財務・戦略的SWOT分析
    Summary Europa Oil & Gas (Holdings) Plc (Europa Oil) is an oil and gas company that offers exploration and development services. The company's services include production and development of conventional and unconventional hydrocarbon assets. It operates its assets in East Midlands basin, Aquitain ba …
  • Therapix Biosciences Ltd (TRPX):製薬・医療:M&Aディール及び事業提携情報
    Summary Therapix Biosciences Ltd (Therapix), formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders. Therapix’s major product candidates include THX-110, for the trea …
  • Bristol-Myers Squibb Co (BMY):企業の財務・戦略的SWOT分析
    Bristol-Myers Squibb Co (BMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Aldi Einkauf GmbH & Co oHG:企業の戦略・SWOT・財務情報
    Aldi Einkauf GmbH & Co oHG - Strategy, SWOT and Corporate Finance Report Summary Aldi Einkauf GmbH & Co oHG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆